On October 24, Gu Bing, Party Secretary and Executive Vice Chairman of the Association for Science and Technology in Pudong New District, Chen Jun, Director of the Innovation Services (Society Academic) Department, and other leaders came to Yuanwu Medicine to carry out research and guidance work. Ouyang Ping, founder and chairman of Yuanwu Medicine, and Dr. Jin Jun, general manager and CTO, accompanied the visit and exchange.

Left: Gu Bing, Party Secretary and Executive Vice Chairman of the Association for Science and Technology in Pudong New District

Right: Chen Jun, Director of the Innovation Services (Academic Society) Department of the Association for Science and Technology in Pudong New District

Yuanwu Medical is a regenerative medicine company focusing on the development and application of iPSC(Induced Pluripotent Stem Cell) technology. iPSC technology belongs to a subdivision track in the field of cell and gene therapy (CGT) and has been a key development field at the forefront of international medicine in recent years., providing new research directions for stem cell biology and regenerative medicine.

Leaders of the Association for Science and Technology first visited the company's Stem Cell Engineering Technology Center. Dr. Jin Jun introduced the entire process of iPS cell drug research and development: from receiving samples to cell culture, to cell reprogramming and inducing differentiation, and finally to testing, release and warehousing.

At the symposium, Ouyang Ping, the founder of the company, introduced in detail the company's core technology, professional team, market expectations, research and development progress, etc., and said that with the guidance and help of the Pudong New District Association for Science and Technology, the company will base itself on its own industrial positioning, carry out various tasks actively, solidly and steadily, deepen scientific research cooperation, strengthen academic exchanges, and contribute to Pudong's scientific and technological innovation and high-quality development.

Secretary Gu Bing expressed his affirmation of Yuanwu Medicine's independent innovation spirit of "breaking stereotypes, seeking truth and being pragmatic". The team pursued scientific research and technological innovation unremittingly, strived to achieve technological breakthroughs in key areas, and also achieved important patent results. He hoped that the company will continue to strive to achieve more breakthroughs from 0 to 1 and contribute more to the construction of a scientific and technological power. At the same time, a series of guidance and suggestions were given on the development stage of the enterprise, from policy support for R & D projects, cultivation and introduction of elite talents, application for scientific research projects and qualification certification, etc., to create a "tailor-made" scientific and technological development comprehensive plan for the enterprise.

About Yuanvore Medicine

Shanghai Yuanvore Medicine Technology Co., Ltd. is a regenerative medicine company focusing on the development and application of iPSC(Induced Pluripotent Stem Cell) technology. It is certified as a national-level technology-based small and medium-sized enterprise. It has the world's leading independent intellectual property rights (5 invention patents have been authorized, 2 of which have applied for PCT), providing solutions for the application of iPSC technology in regenerative medicine to treat chronic degenerative diseases.

"Yuan" is the beginning, and one yuan produces three;"Wu" soil is solid and heavy, giving birth to all things. Yuanwu Medicine uses stem cells as carriers to explore the secrets of life. iPSC provides unlimited possibilities for regenerative medicine with its unique infinite proliferation ability and developmental totality. Together with the world's leading iPSC expert team, we are committed to creating the "Yuanwu Plan". Starting from the concept of "right cells, right functions", we use small molecules to regulate cell fate, and improve target phenotypic cells while accurately obtaining target cells. The productivity of cells provides industrial-friendly regenerative medicine solutions for the treatment of chronic degenerative diseases, and applies empowerment to major health fields such as aging, degradation, and damage, creating disruptive medical value and market value.